Literature DB >> 420982

A reappraisal of the value of carcinoembryonic antigen in the management of patients with various neoplasms.

M J Cooper, C R Mackie, D B Skinner, A R Moossa.   

Abstract

Eight hundred and eight patients with histologically proved malignant disease had carcinoembryonic antigen (CEA) estimations performed at the time of tissue diagnosis. An elevated level was found in 384 of 518 patients with gastrointestinal neoplasms (74 per cent) and in 162 of 290 patients with other neoplasms (56 per cent). No correlation was found between CEA elevations and tumour differentiation. There was a good correlation between tumour staging and CEA levels for patients with colorectal cancer; the more advanced the tumour, the higher the CEA. Several illustrative cases are presented and the role of CEA assay in the diagnosis and management of neoplasia is discussed. CEA assay is a poor screening test for neoplastic disease, but serial CEA monitoring is valuable in the detection of residual or recurrent cancer.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 420982     DOI: 10.1002/bjs.1800660212

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

1.  Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis.

Authors:  Yoshinobu Mitsuyama; Hiroaki Shiba; Koichiro Haruki; Yuki Fujiwara; Kenei Furukawa; Tomonori Iida; Takenori Hayashi; Masaichi Ogawa; Yuichi Ishida; Takeyuki Misawa; Hideyuki Kashiwagi; Katsuhiko Yanaga
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

2.  Serologic markers in the diagnosis and management of pancreatic carcinoma.

Authors:  D K Podolsky
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

3.  Prospective evaluation of some candidate tumor markers in the diagnosis of pancreatic cancer.

Authors:  C R Mackie; A R Moossa; V L Go; G Noble; G Sizemore; M J Cooper; R A Wood; A W Hall; T Waldmann; F Gelder; A H Rubenstein
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

4.  Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

Authors:  H Jalanko; P Kuusela; P Roberts; P Sipponen; C A Haglund; O Mäkelä
Journal:  J Clin Pathol       Date:  1984-02       Impact factor: 3.411

5.  [The value of poly-C-specific serum ribonuclease and CEA in the diagnosis of pancreatic carcinoma (author's transl)].

Authors:  N Hölbling; J Funovics; J Euler; J Karner; G Zöch; G Sauermann
Journal:  Klin Wochenschr       Date:  1981-11-02

6.  Scintigraphic detection of gastric and pancreatic carcinomas with In-111 ZCE 025 monoclonal antibody.

Authors:  H H Abdel-Nabi; A N Schwartz; D G Wechter; C S Higano; J A Ortman-Nabi; M W Unger
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

7.  Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.

Authors:  P Kuusela; C Haglund; P J Roberts; H Jalanko
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

8.  CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas.

Authors:  Ok-Jun Lee; Seung-Myoung Son; Kwon Pyo Hong; Yong-Moon Lee; Min-Young Kim; Jae-Woon Choi; Sang-Jeon Lee; Young-Jin Song; Hak Soon Kim; Wun-Jae Kim; See-Ok Shin; Hyung Geun Song
Journal:  Virchows Arch       Date:  2014-11-27       Impact factor: 4.064

9.  Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.

Authors:  P Kuusela; H Jalanko; P Roberts; P Sipponen; J P Mecklin; R Pitkänen; O Mäkelä
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

10.  Multiple primary malignant neoplasia in three members of a family.

Authors:  G S Kenyon
Journal:  J R Soc Med       Date:  1981-08       Impact factor: 18.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.